Cargando…

Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

Inhibition of intestinal P-glycoprotein might enhance the absorption of orally administered P-glycoprotein substrate drugs. We show here a 10-fold increased oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. These results encourage further research on the...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Asperen, J., van Tellingen, O., Sparreboom, A., Schinkel, A. H., Borst, P., Nooijen, W. J., Beijnen, J. H.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1997
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228133/ https://www.ncbi.nlm.nih.gov/pubmed/9365166

Ejemplares similares

Inhibitory Effects of a Cyclosporin Derivative, SDZ PSC 833, on Transport of Doxorubicin and Vinblastine via Human P‐Glycoprotein
por: Kusunoki, Nobuya, et al.
Publicado: (1998)

Modulation of Multidrug Resistance by SDZ PSC 833 in Leukemic and Solid‐tumor‐bearing Mouse Models
por: Watanabe, Toru, et al.
Publicado: (1996)

Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukaemia.
por: Colombo, T., et al.
Publicado: (1996)

Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein
por: Asperen, J van, et al.
Publicado: (1999)

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice
por: Oostendorp, Roos L., et al.
Publicado: (2010)

Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
por: Tellingen, O van, et al.
Publicado: (1999)

Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.
por: Lehne, G., et al.
Publicado: (1998)

Phase I Study of Intravenous PSC‐833 and Doxorubicin: Reversal of Multidrug Resistance
por: Minami, Hironobu, et al.
Publicado: (2001)

P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo
por: van Tellingen, O, et al.
Publicado: (2003)

CCM 83.3
Publicado: (1983)

Optimization of dose and route of administration of the P‐glycoprotein inhibitor, valspodar (PSC‐833) and the P‐glycoprotein and breast cancer resistance protein dual‐inhibitor, elacridar (GF120918) as dual infusion in rats
por: Rowbottom, Christopher, et al.
Publicado: (2021)

In vitro antitumour activity of the novel imidazoisoquinoline SDZ 62-434.
por: Brunton, V. G., et al.
Publicado: (1993)

SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance.
por: Loor, F., et al.
Publicado: (1992)

Data on the concentrations of etoposide, PSC833, BAPTA-AM, and cycloheximide that do not compromise the vitality of mature mouse oocytes, parthenogenetically activated and fertilized embryos
por: Martin, Jacinta H., et al.
Publicado: (2016)

The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients
por: Malingré, M M, et al.
Publicado: (2001)

Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation
por: Hendrikx, J J M A, et al.
Publicado: (2014)

833. Interaction between Aspergillus fumigatus and non-tuberculous mycobacteria
por: Namie, Hotaka, et al.
Publicado: (2023)

Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG)
por: Kuin, A, et al.
Publicado: (1999)

Intracellular Levels of Two Cyclosporin Derivatives Valspodar (PSC 833) and Cyclosporin A Closely Associated with Multidrug Resistance‐modulating Activity in Sublines of Human Colorectal Adenocarcinoma HCT‐15
por: Uchiyama‐Kokubu, Noriko, et al.
Publicado: (2001)

Oral topotecan: bioavailability and effect of food co-administration
por: Herben, V M M, et al.
Publicado: (1999)

P833: MARCH5 AS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA
por: Bashiri, Hamed, et al.
Publicado: (2023)

Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets.
por: de Wit, R., et al.
Publicado: (1996)

833. Characteristics and Utilization Patterns of Colistin Compared with Newer Agents in Gram-Negative Infections
por: Marcella, Stephen, et al.
Publicado: (2020)

Preclinical Weight Loss Efficacy of AM833 in Combination With Semaglutide in Rodent Models of Obesity
por: John, Linu M, et al.
Publicado: (2021)

Emergence of OXA-833 in Proteus Species at a Tertiary Care Hospital in Dhaka, Bangladesh
por: Jannat, Hasnatul, et al.
Publicado: (2021)

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
por: Schellens, J. H., et al.
Publicado: (1996)

P-glycoprotein polymorphism and levothyroxine bioavailability in hypothyroid patients
por: Öztaş, Ezgi, et al.
Publicado: (2018)

Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?
por: Embaby, Alaa, et al.
Publicado: (2022)

P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure
por: Wang, Jing, et al.
Publicado: (2022)

Discovery of a Flavonoid FM04 as a Potent Inhibitor to Reverse P-Glycoprotein-Mediated Drug Resistance in Xenografts and Improve Oral Bioavailability of Paclitaxel
por: Kan, Jason W. Y., et al.
Publicado: (2022)

P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO)
por: Wang, Yaogeng, et al.
Publicado: (2021)

Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy
por: Scripture, Charity D, et al.
Publicado: (2005)

P-gp and taxanes
por: Hendrikx, Jeroen J.M.A., et al.
Publicado: (2014)

Auxin-Inducible Depletion of the Essentialome Suggests Inhibition of TORC1 by Auxins and Inhibition of Vrg4 by SDZ 90-215, a Natural Antifungal Cyclopeptide
por: Snyder, Nathan A., et al.
Publicado: (2019)

The G2 checkpoint—a node‐based molecular switch
por: de Gooijer, Mark C., et al.
Publicado: (2017)

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients
por: van Andel, L., et al.
Publicado: (2017)

Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes
por: van Eijk, Maarten, et al.
Publicado: (2019)

Bioavailability Enhancement of Paclitaxel via a Novel Oral Drug Delivery System: Paclitaxel-Loaded Glycyrrhizic Acid Micelles
por: Yang, Fu-Heng, et al.
Publicado: (2015)

833 Lactobacillus GG (LGG) Does Not Eliminate Colonization by Vancomycin Resistant Enterococcus (VRE) in Adults with Comorbidities
por: Doron, Shira, et al.
Publicado: (2014)

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a (14)C-microtracer and therapeutic dose in cancer patients
por: van Andel, L., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n6sbc8o7p0gn8etolkvu0c8rlp